Literature DB >> 7688034

Direct evidence for the role of COOH terminus of mouse mammary tumor virus superantigen in determining T cell receptor V beta specificity.

K Yazdanbakhsh1, C G Park, G M Winslow, Y Choi.   

Abstract

It has recently been shown that open reading frames in the 3' long terminal repeats of mouse mammary tumor viruses encode superantigens. These viral superantigens (vSAGs) stimulate most T cells expressing appropriate V beta s almost regardless of the rest of the variable components of the T cell receptors (TCR) expressed by those cells. vSAGs produce a type II integral membrane protein with a nonessential short cytoplasmic domain and a large glycosylated extracellular COOH-terminal domain, which is predicted to interact with major histocompatibility complex class II molecules and the TCR. The transmembrane region of vSAG also has an internal positively charged lysine residue of unknown significance. A set of chimeric and mutant vSAG genes has been used in transfection experiments to show that only the extreme COOH-terminal portion of vSAGs determine their TCR V beta specificities, and to show that the lysine residue in the transmembrane domain is not essential for the function of vSAG.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688034      PMCID: PMC2191119          DOI: 10.1084/jem.178.2.737

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  27 in total

1.  Identification of the region of T cell receptor beta chain that interacts with the self-superantigen MIs-1a.

Authors:  A M Pullen; T Wade; P Marrack; J W Kappler
Journal:  Cell       Date:  1990-06-29       Impact factor: 41.582

Review 2.  T-cell antigen receptor genes and T-cell recognition.

Authors:  M M Davis; P J Bjorkman
Journal:  Nature       Date:  1988-08-04       Impact factor: 49.962

3.  A human beta-actin expression vector system directs high-level accumulation of antisense transcripts.

Authors:  P Gunning; J Leavitt; G Muscat; S Y Ng; L Kedes
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

Review 4.  Properties of the Mls system: a revised formulation of Mls genetics and an analysis of T-cell recognition of Mls determinants.

Authors:  R Abe; R J Hodes
Journal:  Immunol Rev       Date:  1989-02       Impact factor: 12.988

5.  The T-cell repertoire is heavily influenced by tolerance to polymorphic self-antigens.

Authors:  A M Pullen; P Marrack; J W Kappler
Journal:  Nature       Date:  1988-10-27       Impact factor: 49.962

6.  T cell tolerance by clonal elimination in the thymus.

Authors:  J W Kappler; N Roehm; P Marrack
Journal:  Cell       Date:  1987-04-24       Impact factor: 41.582

Review 7.  Molecular genetics of the T cell-receptor beta chain.

Authors:  M M Davis
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

8.  Binding of immunogenic peptides to Ia histocompatibility molecules.

Authors:  B P Babbitt; P M Allen; G Matsueda; E Haber; E R Unanue
Journal:  Nature       Date:  1985 Sep 26-Oct 2       Impact factor: 49.962

9.  Antigen recognition properties of mutant V beta 3+ T cell receptors are consistent with an immunoglobulin-like structure for the receptor.

Authors:  J White; A Pullen; K Choi; P Marrack; J W Kappler
Journal:  J Exp Med       Date:  1993-01-01       Impact factor: 14.307

10.  Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition.

Authors:  J W Kappler; B Skidmore; J White; P Marrack
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

View more
  24 in total

1.  Alternative proteolytic processing of mouse mammary tumor virus superantigens.

Authors:  F Denis; N H Shoukry; M Delcourt; J Thibodeau; N Labrecque; H McGrath; J S Munzer; N G Seidah; R P Sékaly
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Mutational and functional analysis of the C-terminal region of the C3H mouse mammary tumor virus superantigen.

Authors:  T J Wrona; M Lozano; A A Binhazim; J P Dudley
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

3.  In vivo effects of a recombinant vaccinia virus expressing a mouse mammary tumor virus superantigen.

Authors:  C Krummenacher; H Diggelmann; H Acha-Orbea
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

4.  Identification of key amino acids of the mouse mammary tumor virus superantigen involved in the specific interaction with T-cell receptor V(beta) domains.

Authors:  F Baribaud; S Wirth; I Maillard; S Valsesia; H Acha-Orbea; H Diggelmann
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  A novel exogenous mammary tumor virus encoding MHC class II H2E-independent superantigen specific for Tcr-V beta 14.

Authors:  W Wajjwalku; Y Ando; N Niimi; Y Yoshikai
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

6.  Expression of mouse mammary tumor virus superantigen accelerates tumorigenicity of myeloma cells.

Authors:  M Umemura; W Wajjwalku; N Upragarin; T Liu; H Nishimura; T Matsuguchi; Y Nishiyama; G M Wilson; Y Yoshikai
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

7.  Genetics of mouse mammary tumor virus-induced mammary tumors: linkage of tumor induction to the gag gene.

Authors:  L M Hook; Y Agafonova; S R Ross; S J Turner; T V Golovkina
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

8.  Expression of mouse mammary tumor virus superantigen mRNA in the thymus correlates with kinetics of self-reactive T-cell loss.

Authors:  A Barnett; F Mustafa; T J Wrona; M Lozano; J P Dudley
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

9.  Conversion of mouse mammary tumor virus to a lymphomagenic virus.

Authors:  Sanchita Bhadra; Mary M Lozano; Jaquelin P Dudley
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

10.  A novel V beta 2-specific endogenous mouse mammary tumor virus which is capable of producing a milk-borne exogenous virus.

Authors:  N Niimi; W Wajjwalku; Y Ando; N Nakamura; M Ueda; Y Yoshikai
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.